Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic female rat model

G. Mittal, G. Chandraiah, P. Ramarao, M.N.V. Ravi Kumar

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It is believed that estrogen deficiency contributes importantly to the pathogenesis of menopausal metabolic syndrome and symptoms can be ameliorated with estradiol therapy. The present study reports efficacy of 17-β estradiol encapsulated nanoparticles in treating the postmenopausal dyslipidemic condition. Estradiol encapsulated poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared by emulsion-diffusion-evaporation method and evaluated in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model. The results obtained showed that estradiol nanoparticles were equally/more effective in treatment of estrogen deficient hyperlipidemic conditions at three times reduced dose and frequency in comparison to that of drug suspension administered orally. Together, these results demonstrate the ability of nanoparticles in improving oral bioavailability/efficacy of estradiol.
LanguageEnglish
Pages218-223
Number of pages6
JournalPharmaceutical Research
Volume26
Issue number1
DOIs
Publication statusPublished - 2008

Fingerprint

Pharmacodynamics
High Fat Diet
Nutrition
Nanoparticles
Rats
Estradiol
Estrogens
Fats
Polyglactin 910
Emulsions
Biological Availability
Suspensions
Evaporation
Therapeutics
Pharmaceutical Preparations

Keywords

  • bioavailability
  • estrogen therapy
  • lipid profile
  • nanoparticles
  • oral drug delivery

Cite this

@article{bc357f8c66734272a4c0156b87a1df2f,
title = "Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic female rat model",
abstract = "It is believed that estrogen deficiency contributes importantly to the pathogenesis of menopausal metabolic syndrome and symptoms can be ameliorated with estradiol therapy. The present study reports efficacy of 17-β estradiol encapsulated nanoparticles in treating the postmenopausal dyslipidemic condition. Estradiol encapsulated poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared by emulsion-diffusion-evaporation method and evaluated in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model. The results obtained showed that estradiol nanoparticles were equally/more effective in treatment of estrogen deficient hyperlipidemic conditions at three times reduced dose and frequency in comparison to that of drug suspension administered orally. Together, these results demonstrate the ability of nanoparticles in improving oral bioavailability/efficacy of estradiol.",
keywords = "bioavailability, estrogen therapy, lipid profile, nanoparticles, oral drug delivery",
author = "G. Mittal and G. Chandraiah and P. Ramarao and Kumar, {M.N.V. Ravi}",
year = "2008",
doi = "10.1007/s11095-008-9725-x",
language = "English",
volume = "26",
pages = "218--223",
journal = "Pharmaceutical Research",
issn = "0724-8741",
number = "1",

}

Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic female rat model. / Mittal, G.; Chandraiah, G.; Ramarao, P.; Kumar, M.N.V. Ravi.

In: Pharmaceutical Research, Vol. 26, No. 1, 2008, p. 218-223.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pharmacodynamic evaluation of oral estradiol nanoparticles in estrogen deficient (ovariectomized) high-fat diet induced hyperlipidemic female rat model

AU - Mittal, G.

AU - Chandraiah, G.

AU - Ramarao, P.

AU - Kumar, M.N.V. Ravi

PY - 2008

Y1 - 2008

N2 - It is believed that estrogen deficiency contributes importantly to the pathogenesis of menopausal metabolic syndrome and symptoms can be ameliorated with estradiol therapy. The present study reports efficacy of 17-β estradiol encapsulated nanoparticles in treating the postmenopausal dyslipidemic condition. Estradiol encapsulated poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared by emulsion-diffusion-evaporation method and evaluated in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model. The results obtained showed that estradiol nanoparticles were equally/more effective in treatment of estrogen deficient hyperlipidemic conditions at three times reduced dose and frequency in comparison to that of drug suspension administered orally. Together, these results demonstrate the ability of nanoparticles in improving oral bioavailability/efficacy of estradiol.

AB - It is believed that estrogen deficiency contributes importantly to the pathogenesis of menopausal metabolic syndrome and symptoms can be ameliorated with estradiol therapy. The present study reports efficacy of 17-β estradiol encapsulated nanoparticles in treating the postmenopausal dyslipidemic condition. Estradiol encapsulated poly(lactide-co-glycolide) (PLGA) nanoparticles were prepared by emulsion-diffusion-evaporation method and evaluated in estrogen deficient (ovariectomized) high fat diet induced hyperlipidemic rat model. The results obtained showed that estradiol nanoparticles were equally/more effective in treatment of estrogen deficient hyperlipidemic conditions at three times reduced dose and frequency in comparison to that of drug suspension administered orally. Together, these results demonstrate the ability of nanoparticles in improving oral bioavailability/efficacy of estradiol.

KW - bioavailability

KW - estrogen therapy

KW - lipid profile

KW - nanoparticles

KW - oral drug delivery

U2 - 10.1007/s11095-008-9725-x

DO - 10.1007/s11095-008-9725-x

M3 - Article

VL - 26

SP - 218

EP - 223

JO - Pharmaceutical Research

T2 - Pharmaceutical Research

JF - Pharmaceutical Research

SN - 0724-8741

IS - 1

ER -